Angelalign Technology Inc. Reports Robust 2025 Financial Performance and Dividend Announcements
Angelalign Technology Inc. (stock code 6699.HK) published its audited financial results for the fiscal year ended 31 December 2025 on 27 March 2026, followed by dividend declarations the same day. The company, a Chinese‑based medical‑device manufacturer specializing in invisible orthodontic aligners, continues to demonstrate strong growth in both global and domestic markets.
1. Financial Highlights
| Metric | 2025 | Change vs. 2024 |
|---|---|---|
| Total case volume | 532,400 | +48.1 % |
| Revenue | USD 370.3 million | +37.8 % |
| Adjusted net profit | USD 43.8 million | +63.0 % |
These figures, reported by the company’s CEO, Fox Hu, underscore a trajectory driven by “clinical excellence” and an inclusive corporate culture that attracts top talent. The upward momentum in case volume reflects expanding demand for Angelalign’s aligners, while the revenue rise aligns with an increased average selling price per unit, attributed to the company’s focus on high‑quality, customized treatment plans.
2. Strategic Focus on Clinical Collaboration
CEO Fox Hu highlighted the company’s deliberate strategy to engage directly with leading orthodontists in major cities worldwide. By providing high‑quality clinical support and tailored services, Angelalign aims to deepen the trust of practitioners who typically require extensive experience before endorsing new brands. The company’s investment in a global investor base and skilled workforce has enabled significant organizational changes, positioning it to meet the rigorous demands of top‑tier clinicians.
3. Dividend Policy
On 27 March 2026, Angelalign announced both a final and a special dividend for the year ended 31 December 2025:
| Dividend | Amount per share | Payment date |
|---|---|---|
| Final dividend | HKD 0.80 | 26 April 2026 |
| Special dividend | HKD 0.50 | 26 April 2026 |
The declaration of both dividends signals the company’s confidence in its cash‑flow position and its commitment to returning value to shareholders while retaining sufficient capital for continued expansion.
4. Market Context
At the close of 26 March 2026, Angelalign’s share price stood at HKD 66.55, trading within a 52‑week range of HKD 45.75 to HKD 78.85. The company’s market capitalization is approximately HKD 10.4 billion, with a price‑earnings ratio of 60.01. The elevated P/E reflects the market’s anticipation of sustained growth in the orthodontic device sector, driven by rising demand for aesthetic dental solutions in China and abroad.
5. Outlook
The company’s management reiterated its vision of “clinical excellence” as a catalyst for long‑term growth. By continuing to invest in product innovation, clinical partnerships, and operational efficiency, Angelalign expects to sustain its expansion trajectory across both domestic and international markets.
The 2025 results, coupled with the dividend announcements, reinforce Angelalign Technology Inc.’s position as a leading player in the health‑care technology sector, particularly within the growing niche of invisible orthodontic aligners.
